Ken Griffin Delcath Systems, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 11,700 shares of DCTH stock, worth $107,639. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,700
Previous 9,500
23.16%
Holding current value
$107,639
Previous $45,000
115.56%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding DCTH
# of Institutions
58Shares Held
7.84MCall Options Held
118KPut Options Held
69.9K-
Aigh Capital Management LLC Baltimore, MD2.4MShares$22.1 Million7.28% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.67MShares$15.3 Million2.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA996KShares$9.17 Million0.0% of portfolio
-
Essex Investment Management CO LLC Boston, MA336KShares$3.09 Million0.56% of portfolio
-
Geode Capital Management, LLC Boston, MA245KShares$2.25 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $79.1M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...